Troculeucel - NKGen Biotech
Alternative Names: SNK-01; SNK01 - NKGen BiotechLatest Information Update: 28 Apr 2025
At a glance
- Originator NKGen Biotech
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Alzheimer's disease; Solid tumours
- Clinical Phase Unknown Frontotemporal dementia; Stroke
- Preclinical Triple negative breast cancer
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In adults) in Mexico (IV)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
- 03 Mar 2025 Clinical trials in Stroke (Parenteral), prior to March 2025